Immix Biopharma, Inc. IMMX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s EPS (diluted)?
- Immix Biopharma, Inc. (IMMX) reported EPS (diluted) of -$0.18 in Q1 2026.
- How has Immix Biopharma, Inc.'s EPS (diluted) changed year-over-year?
- Immix Biopharma, Inc.'s EPS (diluted) decreased by 20.0% year-over-year, from -$0.15 to -$0.18.
- What is the long-term trend for Immix Biopharma, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s EPS (diluted) has grown at a -39.5% compound annual growth rate (CAGR), from -$6.64 to -$0.89.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.